Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20337710 | 0.90 | IRAK4 (0.41) | IRAK4KCNQ3KCNQ2ROCK2PDE10A | |
| SCHEMBL20337715 | 0.88 | GPR6 (0.39) | IRAK4KCNQ3KCNQ2PDE10AGPR6 | |
| SCHEMBL20337771 | 0.85 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL20337682 | 0.84 | CRACR2A (0.47) | IRAK4KCNQ3KCNQ2ROCK2PDE10A | |
| SCHEMBL20337700 | 0.83 | PDE10A (0.41) | IRAK4KCNQ3KCNQ2ROCK2PDE10A | |
| SCHEMBL20337780 | 0.82 | GPR6 (0.45) | IRAK4PDE10ACYP11B1CYP11B2GPR6 | |
| SCHEMBL20337733 | 0.82 | WDR5 (0.44) | IRAK4KCNQ3KCNQ2ROCK2PDE10A | |
| SCHEMBL20337737 | 0.82 | IRAK4 (0.42) | IRAK4KCNQ3KCNQ2ROCK2PDE10A | |
| SCHEMBL20337718 | 0.81 | GPR6 (0.49) | IRAK4KCNQ3KCNQ2ROCK2PDE10A | |
| SCHEMBL20337734 | 0.78 | PDE10A (0.39) | IRAK4PDE10AGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | disclosed |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) | 2024-03-05 | — | — | US | disclosed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | disclosed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| EP-3562306-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | IRAK4 4090/4885KCNQ3 3581/4885KCNQ2 3140/4885 |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | IRAK4 4090/4885KCNQ3 3581/4885KCNQ2 3140/4885 |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | IRAK4 4090/4885KCNQ3 3581/4885KCNQ2 3140/4885 |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | IRAK4 4090/4885KCNQ3 3581/4885KCNQ2 3140/4885 |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | IRAK4 4090/4885KCNQ3 3581/4885KCNQ2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.